Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IrAE”

47 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 47 results

Testing effectiveness (Phase 2)Looking for participantsNCT06789601
What this trial is testing

Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository

Who this might be right for
MalignancyImmune Related Adverse Events
Brigham and Women's Hospital 100
Not applicableUnknownNCT05288569
What this trial is testing

IrAE Prediction of Anti-PD-1/L1 in Lung Cancer

Who this might be right for
Immune Checkpoint InhibitorsLung Cancer
Peking Union Medical College Hospital 120
Not applicableEnded earlyNCT05699915
What this trial is testing

Extensive CArdioVAscular Characterization and Follow-up of Patients Receiving Immune Checkpoint Inhibitors

Who this might be right for
CancerImmune-related Adverse EventCardiac Abnormalities, Variable+4 more
Algemeen Ziekenhuis Maria Middelares 105
Not applicableUnknownNCT06243250
What this trial is testing

Hyperpolarized 13C-MRI and Metabolomics for Immune-related Adverse Events

Who this might be right for
Immune-related Adverse Event
Chang Gung Memorial Hospital 30
Not applicableEnrolling By InvitationNCT07499128
What this trial is testing

Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event

Who this might be right for
Cytokine Release SyndromeNeoplasmsLymphoma+13 more
National Cancer Institute (NCI) 136
Not applicableLooking for participantsNCT05813418
What this trial is testing

Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment

Who this might be right for
ImmunotherapyImmune Checkpoint InhibitorsImmune-related Adverse Event+1 more
Centre Hospitalier Universitaire, Amiens 150
Not applicableActive Not RecruitingNCT03409016
What this trial is testing

Biomarkers of Immune-Related Toxicity

Who this might be right for
CancerMetastatic Cancer
University of Colorado, Denver 69
Early research (Phase 1)Not Yet RecruitingNCT07694414
What this trial is testing

Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events

Who this might be right for
Immune-Related Adverse Events
Inge Marie Svane 25
Not applicableStudy completedNCT03447483
What this trial is testing

Cohort Study: Modelling Toxicity Processing in Patients Treated by Immunotherapy (MOTIVATE).

Who this might be right for
Solid Tumor
Institut Claudius Regaud 150
Testing effectiveness (Phase 2)Looking for participantsNCT07663422
What this trial is testing

Mycophenolate Mofetil w/ Prednisone for Immune Related Hepatitis From Checkpoint Inhibitor Therapy

Who this might be right for
Immune-mediated HepatitisImmune-related Adverse Event
Fox Chase Cancer Center 31
Not applicableStudy completedNCT05450367
What this trial is testing

Predictive Markers of Response and Toxicity in Patients With a Haematological Malignancy Treated With Immunotherapy.

Who this might be right for
Blood Cancer
Assistance Publique - Hôpitaux de Paris 249
Not applicableStudy completedNCT05700565
What this trial is testing

Treatment of Immune-related Adverse Events Refractory to Standard Therapy and Associated Changes in Immunophenotype

Who this might be right for
Immune-related Adverse Event
Lucie Heinzerling 46
Testing effectiveness (Phase 2)Looking for participantsNCT06278857
What this trial is testing

SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)

Who this might be right for
Endometrial Cancer Stage IMmr DeficiencyEndometrioid Endometrial Adenocarcinoma+1 more
Queensland Centre for Gynaecological Cancer 10
Not applicableStudy completedNCT06247865
What this trial is testing

BIO-CHECKPOINT 0 Biomarkers to Identify Oncology Patients on ICPI at Greater Risk of irAE

Who this might be right for
Neoplasms
Portsmouth Hospitals NHS Trust 120
Not applicableStudy completedNCT03948724
What this trial is testing

Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology

Who this might be right for
Therapeutic Patient EducationImmune Checkpoint InhibitorsMelanoma+4 more
Institut Cancerologie de l'Ouest 412
Testing effectiveness (Phase 2)Looking for participantsNCT05663775
What this trial is testing

Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)

Who this might be right for
Immune-related Adverse EventDiarrheaAdvanced Melanoma+1 more
AHS Cancer Control Alberta 20
Not applicableLooking for participantsNCT05832606
What this trial is testing

Food Intervention to Reduce Immunotherapy ToXicity

Who this might be right for
Immune-related Adverse EventDietary Habits
Universitair Ziekenhuis Brussel 60
Not applicableLooking for participantsNCT06635954
What this trial is testing

A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

Who this might be right for
CancerImmunotherapyPD-1+2 more
Oxford Biodynamics Inc. 2,000
Early research (Phase 1)Not Yet RecruitingNCT07478679
What this trial is testing

Radiation to Treat Joint Damage Caused by Cancer Immunotherapy

Who this might be right for
ArthritisArthropathy
University of Chicago 20
Testing effectiveness (Phase 2)WithdrawnNCT04060407
What this trial is testing

CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)

Who this might be right for
Metastatic Melanoma
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Next Page